S122 THE FIRST-IN-CLASS, ORALLY AVAILABLE BMI-1 MODULATORS PTC-028 AND PTC596 DISPLAY POTENT ACTIVITY IN PRE-CLINICAL MODELS OF MULTIPLE MYELOMA

Autor: Louise Vrancken, H. Breid, D. Arnold, J. Muller, Arnold Bolomsky, W. Hübl, A. Branstrom, H. Ludwig, K. Stangelberger, Elodie Duray, M. Weetall, Marie Lejeune, M. Willheim, N. Zojer, J. Caers

Publikováno v: HemaSphere. 3:13

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc07368de786e2218dfd2db4c9b211d6
https://doi.org/10.1097/01.hs9.0000558708.13526.34

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.

Autor: Wirnsberger G; Apeiron Biologics, Vienna, Austria., Monteil V; Karolinska Institutet and Karolinska University Hospital, Unit of Clinical Microbiology, SE-17182, Stockholm, Sweden., Eaton B; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA., Postnikova E; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA., Murphy M; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA., Braunsfeld B; Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences (BOKU), Austria., Crozier I; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA., Kricek F; NBS-C BioScience & Consulting GmbH, Vienna, Austria., Niederhöfer J; Apeiron Biologics, Vienna, Austria., Schwarzböck A; Apeiron Biologics, Vienna, Austria., Breid H; Apeiron Biologics, Vienna, Austria., Jimenez AS; Apeiron Biologics, Vienna, Austria., Bugajska-Schretter A; Apeiron Biologics, Vienna, Austria., Dohnal A; Apeiron Biologics, Vienna, Austria., Ruf C; NBS-C BioScience & Consulting GmbH, Vienna, Austria., Gugenberger R; Apeiron Biologics, Vienna, Austria., Hagelkruys A; Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria., Montserrat N; Pluripotency for Organ Regeneration, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain., Holbrook MR; NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, MD 21702, USA., Oostenbrink C; Institute for Molecular Modeling and Simulation, University of Natural Resources and Life Sciences (BOKU), Austria., Shoemaker RH; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892., Mirazimi A; Karolinska Institutet and Karolinska University Hospital, Unit of Clinical Microbiology, SE-17182, Stockholm, Sweden., Penninger JM; Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria.; Department of Medical Genetics, Life Sciences Institute, University of British Columbia, Vancouver, Canada.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2021 Sep 10. Date of Electronic Publication: 2021 Sep 10.